EUVIMEDEUVIMED entdecken
Crossref

Blockade of CD155 and Interleukin-6 Suppresses Breast Cancer Cell Growth

Atefeh Khodakarami, Samira Darvishi, Hadi Hassannia, Mohammad Sadeghi, Sana Esmaeeli, Vida Hashemi, Mohammad Hojjat-Farsangi, Farhad Jadidi-Niaragh

International Journal of Drug Research in Clinics · 2023

DOI: 10.34172/ijdrc.2023.e10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Research in Clinics, 2023. Verfasst von Atefeh Khodakarami und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer is the foremost common type of cancer worldwide and the leading cause of death related to cancer. Poliovirus receptor (CD155) or nectin-like molecule-5 expression has been shown to increase in tumor cells and bind to the DNAX accessory molecule (DNAM-1)/T cell immunoreceptor with Ig and ITIM domains (TIGIT)/CD69 ligand present on the surface of T and natural killer cells, increasing inflammatory cytokines, including interleukin 6 (IL-6) in the tumor microenvironment. As a result, we intended to simultaneously target both CD155 and IL-6 as an effective therapeutic approach to prevent breast cancer growth.

Methods

In this study, 4T1 cells were transfected with small interfering RNA (siRNA) molecules against CD155 and IL-6, using lipofectamine (LP). Target gene expression was analyzed using both the real-time polymerase chain reaction (RT-PCR) and an enzyme-linked immunosorbent assay (ELISA). The methyl thiazolyl tetrazolium (MTT) assay also examined the cytotoxic effect of combined therapy.

Results

The results showed that the cells were effectively transfected with LP, resulting in the downregulation of IL-6 and CD155. In addition, the combined silencing of IL-6 and CD155 potently reduced the cellular viability of cancer cells.

Conclusion

These findings revealed that the simultaneous targeting of CD155 and IL-6 in breast cancer cells (4T1) is an innovative and efficient therapy strategy to induce apoptosis in malignant cells.

Zitieren

APA

Khodakarami, A., Darvishi, S., Hassannia, H., Sadeghi, M., Esmaeeli, S., Hashemi, V., Hojjat-Farsangi, M., & Jadidi-Niaragh, F. (2023). Blockade of CD155 and Interleukin-6 Suppresses Breast Cancer Cell Growth. International Journal of Drug Research in Clinics. https://doi.org/10.34172/ijdrc.2023.e10

Vancouver

Khodakarami A, Darvishi S, Hassannia H, Sadeghi M, Esmaeeli S, Hashemi V, et al. Blockade of CD155 and Interleukin-6 Suppresses Breast Cancer Cell Growth. International Journal of Drug Research in Clinics. 2023. doi:10.34172/ijdrc.2023.e10

BibTeX
@article{Khodakarami2023,
  author = {Khodakarami, Atefeh and Darvishi, Samira and Hassannia, Hadi and Sadeghi, Mohammad and Esmaeeli, Sana and Hashemi, Vida and Hojjat-Farsangi, Mohammad and Jadidi-Niaragh, Farhad},
  title = {Blockade of CD155 and Interleukin-6 Suppresses Breast Cancer Cell Growth},
  journal = {International Journal of Drug Research in Clinics},
  year = {2023},
  doi = {10.34172/ijdrc.2023.e10}
}
Kostenlos starten →